Proactive Investors - Run By Investors For Investors

VentriPoint Diagnostics soars as it's set to offer VMS Plus to medics in the US after FDA approval

The group reported further progress on its flagship product, namely FDA approval to sell its VMS Plus machine
VentriPoint Diagnostics soars as it's set to offer VMS Plus to medics in the US after FDA approval
VMS Plus can assess a patient's heart function, expressed as ejection fraction or volumes of any of the four chambers

Medtech group VentriPoint Diagnostics Ltd (CVE:VPT) reported further progress on its flagship product, namely FDA approval to sell its VMS Plus machine with the four-chamber heart analysis system in the USA.

"The VMS Plus is the first simple echocardiography system to be approved by the FDA for the 3-D volumetric analysis of all four chambers of the heart using 2-D ultrasound," said Dr George Adams, chief executive officer of VentriPoint.

READ: VentriPoint Diagnostics to advance AI capabilities in its heart device with new gov't funding

"Now we can offer the VMS Plus to American physicians so they can accurately and easily evaluate and monitor hearts in children and adults during a routine cardiology appointment."

The VMS+ is the first cost-effective and accurate artificial intelligence tool for measuring whole heart function using conventional ultrasound.

The  USA is the largest medical device market in the world with over 40mln cardiac ultrasound exams per year.

Two-dimensional ultrasound is the modern stethoscope and is employed worldwide as the first step in evaluating heart disease.

Dr Adams added: "There is more and more evidence that volumes and function can predict which patients require more or less drugs and more careful monitoring and this what the VMS+ does easily and cost-effectively.  

"Our mission to make it easier for every doctor worldwide to know what is actually happening with a heart without having to send everyone to an MRI has been advanced greatly with this approval.  The rest of the world looks to the USA as a leader in cardiac care and so this will help us elsewhere as well."

Looking ahead,  the company boss said: "We have sales and marketing plan for the USA and are now free to implement it.  

"You are not allowed to even market a device in the USA without approval, but we have a number of leading centres who are aware of the VMS and have been asking when the VMS+ would be available.  We can now actively contact them and solicit orders.  We will be announcing these orders as they come in."

Shares surged almost 29% in Toronto to stand at C$0.38 each.

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
1542204301_heart.jpg
November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use